Ikarian Capital, LLC Sarepta Therapeutics, Inc. Put Options Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	BUY	$67.31 - $124.76 $6.6 Million - $12.2 Million	98,127 Added 2671.58%	101,800 $9.82 Million
Q3 2023 Nov 14, 2023	SELL	$102.5 - $123.59 $12.1 Million - $14.6 Million	-118,427 Reduced 96.99%	3,673 $445,000
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $15.9 Million - $23.5 Million	-149,200 Reduced 54.99%	122,100 $14 Million
Q1 2023 May 15, 2023	BUY	$117.53 - $155.99 $31.9 Million - $42.3 Million	271,300 New	271,300 $37.4 Million
Q1 2021 May 17, 2021	SELL	$72.25 - $168.95 $30 Million - $70.1 Million	-415,000 Reduced 47.65%	455,900 $34 Million
Q4 2020 Feb 12, 2021	BUY	$125.56 - $178.74 $42.8 Million - $60.9 Million	340,800 Added 64.29%	870,900 $148 Million
Q3 2020 Nov 16, 2020	BUY	$127.12 - $172.34 $67.4 Million - $91.4 Million	530,100 New	530,100 $74.4 Million

532

84.5M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $9.15B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.